Stem cell therapy for intrauterine adhesions: a systematic review and meta-analysis of clinical outcomes
Yuan F., Zhang Y., Qian Y., Zhou X., Wang M., Hu H.
Meta-analysis, published in BMC Pregnancy Childbirth (2025) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Meta-analysis
- Journal
- BMC Pregnancy Childbirth (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41390638
- PMCID
- PMC12821970
- DOI
- 10.1186/s12884-025-08271-y
Abstract (original English)
Objective Intrauterine Adhesions (IUA), including Asherman's Syndrome, are a significant cause of female infertility, while stem cell interventions emerge as a promising therapeutic strategy. This meta-analysis aims to systematically evaluate the effectiveness of stem cell interventions for IUA by analyzing various pregnancy outcomes. Methods This meta-analysis systematically searched five databases (PubMed, Web of Science, EMBASE, Scopus, and ProQuest) to identify clinical studies on stem cell interventions for IUA and endometrial repair. Data on cumulative live birth, biochemical pregnancy, clinical pregnancy, implantation rate, early spontaneous abortions, and ectopic pregnancy were extracted and analyzed. Subgroup analyses were conducted based on disease type and stem cell intervention method. Results Out of 211 identified records, 10 studies were included. The overall pooled proportion of cumulative live birth was 0.40 (95% confidence interval (CI): 0.22 to 0.60), with significant heterogeneity (I 2 = 46.2%). Subgroup analysis showed the highest live birth rates in "General IUA" (0.57) and with "Autologous Cells with Scaffold/Matrix" (0.5632). Controlled trials demonstrated a significant benefit of stem cell therapy for live birth (odds ratio (OR) = 2.2535, 95% CI: 1.1750 to 4.3221). The pooled proportion for cumulative biochemical pregnancy was 0.6053 (95% CI: 0.4445 to 0
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.